Pharmaceutical amorphous solid dispersions (ASDs) represent a widely used technology to increase the bioavailability of active pharmaceutical ingredients (APIs). ASDs are based on an amorphous API dispersed in a polymer, and their stability is driven by the presence of strong intermolecular interactions between these two species (e.g., hydrogen bond, electrostatic interactions, etc.). The understanding of these interactions at the atomic level is therefore crucial, and solid-state nuclear magnetic resonance (NMR) has demonstrated itself as a very powerful technique for probing API-polymer interactions. Other reviews have also reported exciting approaches to study the structures and dynamic properties of ASDs and largely focused on the study...
Amorphous solid dispersions have been widely applied to improve the oral bioavailability of BCS Clas...
University of Minnesota Ph.D. dissertation. October 2016. Major: Pharmaceutics. Advisor: Dr. Raj Sur...
Poor aqueous solubility of an active pharmaceutical ingredient (API) is a significant hurdle during ...
Low aqueous solubility of active pharmaceutical ingredients (APIs) presents one of the greatest and ...
Over the past few decades, amorphous solid dispersions (ASDs) have been of great interest to pharmac...
Hydroxypropylmethylcellulose (HPMC) acetyl succinate (HPMC-AS) is a key polymer used for the enablem...
The bioavailability of insoluble crystalline active pharmaceutical ingredients (APIs) can be enhance...
Amorphous formulations, including amorphous solid dispersions (ASDs), consisting of the active pharm...
Amorphous drug delivery systems are increasingly utilized to enhance aqueous solubility and oral bio...
Many pharmaceutical compounds being developed in recent years are poorly soluble in water. This has ...
Using the amorphous state of APIs has become a very beneficial strategy to overcome the solubility c...
Amorphous solid dispersions (ASDs) are one of the frontier strategies to improve solubility and diss...
Poorly water-soluble drugs pose a significant challenge to developability due to poor oral absorptio...
Poor physical stability is a limiting factor in the pharmaceutical development of APIs. Amorphous d...
Solid dispersions of active pharmaceutical ingredients are of increasing interest due to their versa...
Amorphous solid dispersions have been widely applied to improve the oral bioavailability of BCS Clas...
University of Minnesota Ph.D. dissertation. October 2016. Major: Pharmaceutics. Advisor: Dr. Raj Sur...
Poor aqueous solubility of an active pharmaceutical ingredient (API) is a significant hurdle during ...
Low aqueous solubility of active pharmaceutical ingredients (APIs) presents one of the greatest and ...
Over the past few decades, amorphous solid dispersions (ASDs) have been of great interest to pharmac...
Hydroxypropylmethylcellulose (HPMC) acetyl succinate (HPMC-AS) is a key polymer used for the enablem...
The bioavailability of insoluble crystalline active pharmaceutical ingredients (APIs) can be enhance...
Amorphous formulations, including amorphous solid dispersions (ASDs), consisting of the active pharm...
Amorphous drug delivery systems are increasingly utilized to enhance aqueous solubility and oral bio...
Many pharmaceutical compounds being developed in recent years are poorly soluble in water. This has ...
Using the amorphous state of APIs has become a very beneficial strategy to overcome the solubility c...
Amorphous solid dispersions (ASDs) are one of the frontier strategies to improve solubility and diss...
Poorly water-soluble drugs pose a significant challenge to developability due to poor oral absorptio...
Poor physical stability is a limiting factor in the pharmaceutical development of APIs. Amorphous d...
Solid dispersions of active pharmaceutical ingredients are of increasing interest due to their versa...
Amorphous solid dispersions have been widely applied to improve the oral bioavailability of BCS Clas...
University of Minnesota Ph.D. dissertation. October 2016. Major: Pharmaceutics. Advisor: Dr. Raj Sur...
Poor aqueous solubility of an active pharmaceutical ingredient (API) is a significant hurdle during ...